Literature DB >> 8394197

Gross pathologic types of hepatocellular carcinoma in Italian patients. Relationship with demographic, environmental, and clinical factors.

F Trevisani1, P Caraceni, M Bernardi, P E D'Intino, V Arienti, P Amorati, G F Stefanini, G Grazi, A Mazziotti, L Fornalè.   

Abstract

BACKGROUND: The prevalence of the different hepatocellular carcinoma (HCC) macroscopic types, and the association between these types and age, gender, blood group, alcohol and coffee intake, smoking habit, hepatitis virus markers, underlying cirrhosis, and cancer histologic type were retrospectively assessed in 416 unselected patients (321 with cirrhosis).
METHODS: The gross pathologic types of HCC were assessed by ultrasonography combined, in most cases, with computed tomography and angiography.
RESULTS: Solitary HCC was the most common cancer type (54.8%), followed by the multinodular (31%), diffuse (7.7%), and massive (6.5%) types. Cirrhosis and blood group other than O were independent risk factors for multinodular HCC (relative risk [RR] 1.6, P < 0.05; and RR 1.7, P < 0.005, respectively); the absence of cirrhosis and a heavy smoking habit were risk factors for the massive type (RR 4.9, P < 0.001; and RR 3.3, P < 0.01, respectively); and blood group O for the solitary type (RR 1.4, P < 0.001). The prevalence of highly undifferentiated cells increased as the tumor size did, so that grade IV cell atypia was associated with massive size of the carcinoma (P < 0.05). In cirrhotic patients, advanced liver dysfunction was associated with diffuse HCC (P < 0.05). As far as solitary HCC is concerned, the tumor size was greater in noncirrhotic than in cirrhotic patients (7 +/- 0.4 cm versus 4.8 +/- 0.15, P < 0.001).
CONCLUSIONS: In Italian patients, HCC presents most frequently as a solitary nodule. The presence or absence of cirrhosis, blood group, and smoking habit can influence the likelihood of developing certain HCC shapes. The probability of harboring highly undifferentiated cells increases as the cancer increases in size. In cirrhosis, advanced liver dysfunction may predispose to diffuse HCC.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8394197     DOI: 10.1002/1097-0142(19930901)72:5<1557::aid-cncr2820720512>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  32 in total

1.  Well-differentiated hepatocellular carcinoma smaller than 15 mm in diameter totally eradicated with percutaneous ethanol injection instead of radiofrequency ablation.

Authors:  Soo Ryang Kim; Susumu Imoto; Taisuke Nakajima; Kenji Ando; Keiji Mita; Miyuki Taniguchi; Noriko Sasase; Toshiyuki Matsuoka; Masatoshi Kudo; Yoshitake Hayashi
Journal:  Hepatol Int       Date:  2009-03-21       Impact factor: 6.047

Review 2.  Smoking and the digestive system.

Authors:  T Kamada; S Kawano; S Tsuji
Journal:  J Gastroenterol       Date:  1995-12       Impact factor: 7.527

Review 3.  Magnetic resonance imaging of the cirrhotic liver: An update.

Authors:  Agnes Watanabe; Miguel Ramalho; Mamdoh AlObaidy; Hye Jin Kim; Fernanda G Velloni; Richard C Semelka
Journal:  World J Hepatol       Date:  2015-03-27

Review 4.  Infiltrating hepatocellular carcinoma: seeing the tree through the forest.

Authors:  Aram Demirjian; Peter Peng; Jean-Francois H Geschwind; David Cosgrove; Jacob Schutz; Ihab R Kamel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2011-07-02       Impact factor: 3.452

5.  Diffuse infiltrative hepatocellular carcinoma: assessment of presentation, treatment, and outcomes.

Authors:  Peter J Kneuertz; Aram Demirjian; Amin Firoozmand; Celia Corona-Villalobos; Nikhil Bhagat; Joseph Herman; Andrew Cameron; Ahmet Gurakar; David Cosgrove; Michael A Choti; Jean-Francois H Geschwind; Ihab R Kamel; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2012-04-03       Impact factor: 5.344

6.  Inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis.

Authors:  Su-jong Yu; Jung-hwan Yoon; Jeong-hoon Lee; Sun-jung Myung; Eun-sun Jang; Min-sun Kwak; Eun-ju Cho; Ja-june Jang; Yoon-jun Kim; Hyo-suk Lee
Journal:  Acta Pharmacol Sin       Date:  2011-06-13       Impact factor: 6.150

7.  Transarterial chemoembolization vs. conservative treatment for unresectable infiltrating hepatocellular carcinoma: A retrospective comparative study.

Authors:  Qiang-Sheng Dai; Hong-Lin Gu; Sheng Ye; Yao-Jun Zhang; Xiao-Jun Lin; Wan Yee Lau; Zhen-Wei Peng; Min-Shan Chen
Journal:  Mol Clin Oncol       Date:  2014-08-18

8.  Inverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma.

Authors:  Umut Sarpel; Diego Ayo; Iryna Lobach; Ruliang Xu; Elliot Newman
Journal:  HPB (Oxford)       Date:  2012-06-27       Impact factor: 3.647

9.  Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma.

Authors:  Neil Mehta; Nicholas Fidelman; Monika Sarkar; Francis Y Yao
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-17       Impact factor: 11.382

10.  Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization.

Authors:  Eun Sun Jang; Jung-Hwan Yoon; Jin Wook Chung; Eun Ju Cho; Su Jong Yu; Jeong-Hoon Lee; Yoon Jun Kim; Hyo-Suk Lee; Chung Yong Kim
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-03       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.